LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "v600 mutant" as a keyword



The effects of dabrafenib and/or trametinib treatment in Braf V600-mutant glioma: a systematic review and meta-analysis

Sign Up to like & get
recommendations! Published in 2024 at "Neurosurgical Review"

DOI: 10.1007/s10143-024-02664-x

Abstract: This study aimed to evaluate the effects of dabrafenib and/or trametinib therapy in BRAF v600-mutant glioma treatment. PubMed, the Cochrane Library, EMBASE and Web of Science were searched from inception to Sep 2023. Inclusion criteria… read more here.

Keywords: treatment; dabrafenib trametinib; mutant glioma; v600 mutant ... See more keywords

Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanoma.

Sign Up to like & get
recommendations! Published in 2019 at "European journal of cancer"

DOI: 10.1016/j.ejca.2018.12.015

Abstract: BACKGROUND Primary findings from the METRIC (TMT212A2301) study demonstrated that trametinib improved progression-free survival (PFS) and overall survival (OS) compared with chemotherapy in patients with unresectable or metastatic cutaneous melanoma with a BRAF V600 E/K mutation.… read more here.

Keywords: melanoma; patients braf; year; braf v600 ... See more keywords

Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma.

Sign Up to like & get
recommendations! Published in 2020 at "European journal of cancer"

DOI: 10.1016/j.ejca.2020.04.044

Abstract: PURPOSE This study (NCT02083354) assessed the efficacy and safety of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma. METHOD Overall, 77 patients of East Asian origin (including 61 from Mainland… read more here.

Keywords: braf v600; cutaneous melanoma; v600 mutant; mutant cutaneous ... See more keywords

Abstract CT069: Randomized phase 3 study (STARBOARD) evaluating encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for first-line treatment of unresectable locally advanced or metastatic BRAF V600-mutant melanoma

Sign Up to like & get
recommendations! Published in 2023 at "Cancer Research"

DOI: 10.1158/1538-7445.am2023-ct069

Abstract: Background BRAF V600 mutations are frequently found in metastatic melanoma. This mutation constitutively activates the MAPK pathway, which leads to melanoma progression. Patients with BRAF V600-mutant metastatic melanoma typically receive BRAF inhibitors (BRAFi) + MEK… read more here.

Keywords: bini; v600 mutant; braf v600; melanoma ... See more keywords

Abstract 5847: Characterizing mechanisms of BRAF/MEK inhibitor resistance in BRAF V600 mutant colorectal cancer vs. melanoma

Sign Up to like & get
recommendations! Published in 2024 at "Cancer Research"

DOI: 10.1158/1538-7445.am2024-5847

Abstract: Background: BRAF V600 mutations comprise ~80% of all oncogenic BRAF mutations in metastatic colorectal cancer (mCRC). While most cancers with BRAF V600 mutations can be effectively treated with combined BRAF and MEK inhibition, BRAF V600… read more here.

Keywords: braf; crc; v600 mutant; braf mek ... See more keywords

Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma

Sign Up to like & get
recommendations! Published in 2022 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.21.01601

Abstract: PURPOSE Preclinical data suggest the combination of an anti–programmed death receptor 1 antibody plus dabrafenib and trametinib to have superior antitumor activity compared with dabrafenib plus trametinib alone. These observations are supported by translational evidence… read more here.

Keywords: braf v600; melanoma; v600 mutant; plus dabrafenib ... See more keywords

COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600–Mutant Melanoma

Sign Up to like & get
recommendations! Published in 2022 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.21.02659

Abstract: PURPOSE Combination treatment with BRAF and MEK inhibitors has demonstrated benefits on progression-free survival (PFS) and overall survival (OS) and is a standard of care for the treatment of advanced BRAF V600–mutant melanoma. Here, we… read more here.

Keywords: year; braf v600; encorafenib; v600 mutant ... See more keywords